Clarifying stem-cell therapy's benefits and risks

New England Journal of Medicine

Volumn 376, Issue 11, 2017, Pages 1007-1009

  Marks, Peter W ^a   Witten, Celia M ^a   Califf, Robert M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; EDITORIAL; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HUMAN; PATIENT CARE; PATIENT SAFETY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION; THERAPY EFFECT; ADVERSE EFFECTS; STEM CELL RESEARCH;

EVIDENCE-BASED MEDICINE; HUMANS; RISK ASSESSMENT; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

EID: 85015901783     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1613723     Document Type: Editorial

References (5)

1. Nguyen PK, Rhee JW, Wu JC. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol 2016; 1: 831-41.
2. Locatelli F, Algeri M, Trevisan V, Bertaina A. Remestemcel-L for the treatment of graft versus host disease. Expert Rev Clin Immunol 2016; 29: 1-14.
3. Berkowitz AL, Miller MB, Mir SA, et al. Glioproliferative lesion of the spinal cord as a complication of "stem-cell tourism." N Engl J Med 2016; 375: 196-8.
4. Thirabanjasak D, Tantiwongse K, Thorner PS. Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol 2010; 21: 1218-22.
5. Albini T, Kuriyan AE, Townsend JH, et al. Vision loss consequent to intravitreal stem cell injection. Presented at the American Academy of Ophthalmology Annual Meeting, Las Vegas, November 13-14, 2015.